Microwave ablation with or without furmonertinib for early-stage lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding a targeted therapy pill (furmonertinib) to microwave ablation (a needle-based treatment that heats and destroys the tumor) works better than ablation alone for early-stage lung cancer with EGFR mutations. It may help people who cannot have surgery or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage non-small cell lung cancer (NSCLC) with a tumor size of 5 cm or smaller.
- Your tumor has an EGFR mutation (either exon 19 deletion or exon 21 L858R).
- You are 18 years or older and generally able to care for yourself (ECOG score 0-2).
- You are not able to have surgery or radiation, or you have chosen not to have them.
- You have not taken EGFR-targeted pills (like erlotinib, gefitinib, or osimertinib) before.
- You are willing to undergo ablation therapy and follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a targeted drug (furmonertinib) combined with other treatments before surgery for lung cancer with an EGFR mutation. The goal is to shrink the tumor and make surgery more effective.
This trial tests whether adding radiation therapy to the targeted drug furmonertinib can better control advanced lung cancer that has spread to the lining around the lungs (pleural effusion). The main goal is to improve tumor response and possibly reduce future fluid build-up.
This trial tests whether a targeted pill (furmonertinib) combined with local treatments like radiation or heat/cold to destroy the tumor can help people with early-stage lung cancer that has specific genetic changes (EGFR mutations). It aims to control the cancer without surgery.
This trial tests a minimally invasive procedure using microwave energy to destroy small lung tumors, guided by a thin tube through the airways. It may be an option if you can't have standard surgery or radiation, or choose not to.
This Phase 2 trial studies furmonertinib alone or with other treatment options to control advanced lung cancer that has specific EGFR gene changes. It may help by targeting the cancer-driving EGFR mutation, especially in people whose mutation is confirmed by a ctDNA blood test.
This trial tests combining microwave ablation (a procedure that uses heat to destroy tumors) with immunotherapy (drugs that help your immune system fight cancer), with or without drugs that stop blood vessel growth. The goal is to see if this combination is safe and effective for people with advanced lung or liver cancer.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.